Abstract
Global concerns arose as the emerged and rapidly spreading SARS-CoV-2 Delta variant. To date, few data on routine diagnostic performance for Delta are available. Here, we investigate the analytical performance of eleven commercially available antigen-detecting rapid diagnostic tests (Ag-RDTs) for Delta VOC in comparison with current and earlier VOCs (Alpha, Beta and Gamma) and early pandemic variant using cultured SARS-CoV-2. Comparable sensitivity was observed for Delta for the majority of Ag-RDTs.
The study
The emergence of novel SARS-CoV-2 variants of concern (VOCs) requires thorough investigation of altered biological properties, including a potential impact on diagnostic performance. The gold standard method for SARS-CoV-2 detection is reverse-transcriptase polymerase chain reaction (RT-PCR) testing. SARS-CoV-2 antigen rapid diagnostic tests (Ag-RDT) contribute to increasing access to testing individuals suspected to have coronavirus infection and provide results quickly1,2. Ag-RDTs enable sensitive detection of high viral loads (in the range of Ct values ≤25 or >106 RNA copies/mL)3. Although sensitivity is lower compared to RT-PCR testing, Ag-RDTs offer laboratory-independent results at the point of care and are powerful tools for rapid and more affordable public health interventions4. However, the majority of Ag-RDT validation studies were prior to the emergence of the SARS-CoV-2 Delta VOC 5,2. To inform on the performance of Ag-RDTs on the circulating VOCs, we have performed recently, an analytical sensitivity testing of nine commercially available Ag-RDTs for the first three VOCs (Alpha, Beta and Gamma) and one former variant of interest (Zeta) that was circulating at the time of the study2.
In the present analysis, we have now added the Delta variant using cultured SARS-CoV-2, in comparison with earlier VOCs (Alpha, Beta and Gamma) and early-pandemic variant (B.1.610). All viruses were isolated from clinical samples that were fully sequenced, and isolates were grown in Vero-E6 cell line as described previously2. Infectious titers (quantified by plaque titration using Vero-E6 cell line) for variants used in this study were from 1.72E+04 PFU/mL and corresponded to 1.40E+08, 5.00E+06, 1.50E+07, 2.00E+08 and 1.00E+06 RNA copies/mL of virus stocks for B.1.610, Alpha, Beta, Gamma and Delta variant respectively.
All Ag-RDT assays were performed according to the manufacturers’ instructions and to the procedures described previously, under BSL3 conditions 2. Ag-RDT buffer without virus was used as a negative control. Results were read independently by two individuals. Any visible test band in the presence of a visible control band was considered as positive.
Performance of the tests to detect the Delta variant was comparable to the other variants, for the majority of Ag-RDTs. A single test, Sure Status Ag Test (Premier Medical Corporation Ltd.) showed a higher sensitivity for the Alpha, Beta and Gamma than for the Delta variant. Conversely, Flowflex Ag Test (ACON) demonstrated a higher sensitivity for Delta compared to other Ag-RDT kits (Figure). In comparison to B.1.610, the Delta variant, similar to Alpha, Beta and Gamma presented higher sensitivity.
Heat map of analytical sensitivity of eleven Ag-RDTs assays with SARS-CoV-2 variants Alpha, Beta Gamma and Delta in comparison to an early-pandemic SARS-CoV-2 isolate (B.1.610).
(A) Heat map based on CT value. (B) Heat map based on Log10 PFU/mL.
Ag-RDTs used were: I) Panbio COVID-19 Ag Rapid test device (Abbott); II) Standard Q COVID-19 Ag (SD Biosensor/Roche); III) Sure Status (Premier Medical Corporation); IV) NowCheck Covid-19 Ag test (Bionote); V) 2019-nCoV Antigen test (Wondfo); VI) Global Access Diagnostics Ltd (Mologic); VII) Beijng Tigsun Diagnostics Co. Ltd (Tigsun) ; VIII) Nal Von Minden GmbH (Nadal); IX) CTK biotech (Onsite); X) Novel Coronavirus 2010-nCOV Antigen Test (Hotgen); XI) ACON biotech (Flowflex).
* Sensitivity of Ag-RDT tests I, II, III, IV and V for variants Alpha, Beta, Gamma and B.1.610 have already been shown before but were added here for consistency reasons and clarity of the figure.2
In this study, the accuracy of eleven Ag-RDTs (5 of them were used in our previous study2) to detect cultured SARS-CoV-2 variants was determined. This may be a proxy for clinical accuracy, but is not a replacement for clinical evaluations. Nevertheless, we showed here that, despite slight differences in sensitivity, Ag-RDTs remain in principle effective to detect all VOCs, including the Delta variant and can be used for diagnosis to control the spread of SARS-CoV-2.
Data Availability
The authors confirm that the data supporting the findings of this study are available within the article.
Funding
This work was supported by the Swiss National Science Foundation (grant number 196383), the Fondation Ancrage Bienfaisance du Groupe Pictet, and FIND, the global alliance for diagnostics. The Swiss National Science Foundation and the Fondation Ancrage Bienfaisance du Groupe Pictet had no role in data collection, analysis, or interpretation. Antigen rapid diagnostic tests were provided by FIND and FIND was involved in methodology, data analysis and interpretation. CE is an employee of FIND.
Conflicts of Interest
The authors declare no competing interests.